United Kingdom: Life Sciences, Biotechnology & Nanotechnology

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Tyruko And Tysabri: Biosimilars And Their Differences
An investigation is underway after multiple sclerosis patients in the UK reported adverse effects following a switch from the originator medicine Tysabri to its biosimilar Tyruko. Despite regulatory approval confirming no clinically meaningful differences between the two natalizumab-based treatments, subtle variations in manufacturing processes, formulation buffers, and molecular characteristics may explain why some patients have experienced worsening symptoms or side effects.
United Kingdom Healthcare
B
Boult Wade Tennant
Article
Substance Or Device? Decoding Medical Use Claims Under The European Patent Convention
The European Patent Convention allows medical use claims for substances and compositions, but not devices. Recent case law has shifted the approach to determining what qualifies as a "substance or composition," moving away from mode-of-action analysis toward examining the claimed material itself. This evolution raises critical questions about claim drafting and the scope of patent protection for medical technologies.
United Kingdom IP
MC
Marks & Clerk
Article
Perfect Storm - Four Drivers Behind The MRNA Litigation Wave
The COVID-19 pandemic thrust mRNA technology into the global spotlight, transforming decades of foundational research into commercially valuable vaccines almost overnight. This rapid commercialization, combined with enormous revenues and a complex web of overlapping patents, has triggered an unprecedented wave of intellectual property disputes that is reshaping how value is allocated across the biotechnology industry and determining who controls access to next-generation RNA-based medicines.
United Kingdom IP
PC
Potter Clarkson
Article
Drug Repurposing In The Age Of AI: Lessons From COVID-19 And The Future Of Second Medical Use Innovation
Artificial intelligence is transforming how pharmaceutical companies identify new therapeutic uses for existing drugs, but this acceleration creates complex intellectual property challenges. As computational methods rapidly generate repurposing candidates, innovators must navigate the tension between filing early to secure priority and waiting for sufficient validation data, while ensuring their second medical use patents provide meaningful commercial protection in an increasingly competitive landscape.
United Kingdom IP
PC
Potter Clarkson
See more

Latest Videos

See more